Management of coronary artery disease

Safri, Zainal

doi:10.1088/1755-1315/125/1/012125

Cited by 2 publications

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The rate of morbidity and mortality is high, the charges incurred for the treatment manner are also very high, thus giving a bad impact on the welfare and quality of life both in patients, families, and health costs borne by the state. The perfect management can limit the number of losses [1] . Percutaneous coronary intervention [PCI] additionally regarded as coronary angioplasty, is a nonsurgical method for treating obstructive coronary artery disease, consisting of unstable angina, acute myocardial infarction [MI], and Multivessel coronary artery disorder [CAD] [2] .…”

Section: Introductionmentioning

confidence: 99%

Comparison between a Bare–Metal Stents and Drug Eluting Stents in patients undergoing Percutaneous Coronary Intervention.

Al-Sayed¹

2020

International Journal of Medical Arts

View full text Add to dashboard Cite

Background: little researches have directly compared second-generation drug-eluting stents with each other or with baremetal stents. Aim of the work: To compare between outcomes after implantation of bare-metal stents [BMS] and two kinds of 2 nd generation drug eluting stents [DES] [Zotarolimus-Eluting Stents [ZES], and A Everolimus-Eluting Stents [EES]] in patients undergoing percutaneous coronary intervention. Patients and Methods: 160 Ischemic Heart Disease [IHD] patients undergoing PCI with 2 nd generation DES implantation [80 ZES and 80 EES] were analyzed against 50 IHD patients undergoing PCI with BMS implantation. Each patients group received up to 6 [in BMS group] or 24 months [in ZES and EES groups] of clopidogrel therapy. The key efficacy endpoint was the 24 months major adverse cardiac event [MACE] [death, myocardial infarction, or target lesion revascularization], whereas stent thrombosis [ST] was the safety endpoint. Results: The MACE rate was lowest in EES [19%; χ2= 7.661], highest in BMS [41.7%; χ2 =7.661], and intermediate in ZES [28.2%; χ2= 7.661] group with significant P Value =0.002.The 2-year incidence of ST in the EES group [1.3%] was similar to that in the ZES-S group [2.2%], whereas it was lower in contrast with BMS [7.5%] groups, with significant P value= 0.004]. Conclusion: DES have more efficacy and safety than BMS as EES have lowest MACE and ST rate while BMS have the highest rate and ZES have intermediate rate while the three stent groups have similar rate of mortality at 2 years follow up.

show abstract

Section: Introductionmentioning

confidence: 99%

Comparison between a Bare–Metal Stents and Drug Eluting Stents in patients undergoing Percutaneous Coronary Intervention.

Al-Sayed¹

2020

International Journal of Medical Arts

View full text Add to dashboard Cite

show abstract

Current Landscape of Gene Therapy for the Treatment of Cardiovascular Disorders

Wal,

Aziz,

Singh

et al. 2024

CGT

View full text Add to dashboard Cite

Cardiovascular disorders (CVD) are the primary cause of death worldwide. Multiple factors have been accepted to cause cardiovascular diseases; among them, smoking, physical inactivity, unhealthy eating habits, age, and family history are flag-bearers. Individuals at risk of developing CVD are suggested to make drastic habitual changes as the primary intervention to prevent CVD; however, over time, the disease is bound to worsen. This is when secondary interventions come into play, including antihypertensive, anti-lipidemic, anti-anginal, and inotropic drugs. These drugs usually undergo surgical intervention in patients with a much higher risk of heart failure. These therapeutic agents increase the survival rate, decrease the severity of symptoms and the discomfort that comes with them, and increase the overall quality of life. However, most individuals succumb to this disease. None of these treatments address the molecular mechanism of the disease and hence are unable to halt the pathological worsening of the disease. Gene therapy offers a more efficient, potent, and important novel approach to counter the disease, as it has the potential to permanently eradicate the disease from the patients and even in the upcoming generations. However, this therapy is associated with significant risks and ethical considerations that pose noteworthy resistance. In this review, we discuss various methods of gene therapy for cardiovascular disorders and address the ethical conundrum surrounding it.

show abstract

Management of coronary artery disease

Cited by 2 publications

References 12 publications

Comparison between a Bare–Metal Stents and Drug Eluting Stents in patients undergoing Percutaneous Coronary Intervention.

Comparison between a Bare–Metal Stents and Drug Eluting Stents in patients undergoing Percutaneous Coronary Intervention.

Current Landscape of Gene Therapy for the Treatment of Cardiovascular Disorders

Contact Info

Product

Resources

About